Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"The Lancet. Oncology"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject&page=5
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject&page=5
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject&page=5
PubPharm (588)
41
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091) : an interim analysis of a randomised, triple-blind, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
O'Brien, M.
|
Paz-Ares, L.
|
Marreaud, S.
| +19
CommentIn: Lancet Oncol. 2022 Dec;23(12):e528. - PMID 36455577
Wird geladen...
42
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART) : a randomised, open-label, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Gu, W.
|
Han, W.
|
Luo, H.
| +24
CommentIn: Lancet Oncol. 2022 Oct;23(10):1234-1235. - PMID 36075259
Wird geladen...
43
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302) : a multicentre, open-label, randomised, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Westeel, V.
|
Foucher, P.
|
Scherpereel, A.
| +33
CommentIn: Lancet Oncol. 2022 Sep;23(9):1115-1116. - PMID 35964619
Wird geladen...
44
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31) : first interim results from a randomised, double-blind, multicentre, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Lu, S.
|
Wu, L.
|
Jian, H.
| +24
CommentIn: Lancet Oncol. 2022 Sep;23(9):1113-1114. - PMID 35908559
Wird geladen...
45
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564) : 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Powles, T.
|
Tomczak, P.
|
Park, S.
| +119
CommentIn: Lancet Oncol. 2022 Sep;23(9):1110-1111. - PMID 36055297
Wird geladen...
46
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Kelley, R.
|
Rimassa, L.
|
Cheng, A.
| +19
CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015
Wird geladen...
47
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) : a randomised, controlled, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Tam, C.
|
Brown, J.
|
Kahl, B.
| +28
CommentIn: Lancet Oncol. 2022 Aug;23(8):965-967. - PMID 35810752
Wird geladen...
48
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04) : a randomised, multicentre, open-label phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Pautier, P.
|
Italiano, A.
|
Piperno-Neumann, S.
| +39
CommentIn: Lancet Oncol. 2022 Oct;23(10):e442. - PMID 36174623
Wird geladen...
49
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) : long-term follow-up results from an open-label, randomised, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Motzer, R.
|
Powles, T.
|
Burotto, M.
| +16
ErratumIn: Lancet Oncol. 2022 Jul;23(7):e319. - PMID 35772462
Wird geladen...
50
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8) : overall survival results from an open-label, randomised, controlled, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Clamp, A.
|
James, E.
|
McNeish, I.
| +29
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[59]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: The Lancet. Oncology
Medienart
588
Aufsätze
577
E-Artikel
577
E-Ressourcen
11
Gedruckte Aufsätze
Zeitschriftentitel
The Lancet. Oncology
Thema
588
Clinical Trial, Phase III
576
Journal Article
562
Randomized Controlled Trial
470
Research Support, Non-U.S. Gov't
426
Multicenter Study
223
Comparative Study
105
Antibodies, Monoclonal, Humanized
90
EC 2.7.10.1
80
Antineoplastic Agents
67
Cisplatin
67
Q20Q21Q62J
61
Fluorouracil
61
U3P01618RT
59
Receptor, ErbB-2
51
Taxoids
48
15H5577CQD
48
Docetaxel
46
P88XT4IS4D
46
Paclitaxel
44
Protein Kinase Inhibitors
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
156
2020-
409
2010-2019
23
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
588
Englisch
Haven't found what you're looking for?
Wird geladen...